Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major Depressive Disorder
An 8-week, Randomized, Double-blind, Fixed Dosage, Placebo-controlled, Parallel-group, Multi-center Study of the Efficacy, Safety and Tolerability of Agomelatine 25 mg and 50 mg in the Treatment of Major Depressive Disorder (MDD) Followed by a 52-week, Open-label Extension (CAGO178A2301E)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Bayamon, Puerto Rico, 00959
- Novartis Investigative Site
-
Rio Piedras, Puerto Rico
- Novartis Investigative Site
-
-
-
-
Arizona
-
Scottsdale, Arizona, United States, 85251
- Novartis Investigative Site
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72205
- Novartis Investigative Site
-
-
California
-
Cerritos, California, United States, 90703
- Novartis Investigative Site
-
El Centro, California, United States, 92243
- Novartis Investigative Site
-
Garden Grove, California, United States, 92845
- Novartis Investigative Site
-
Irvine, California, United States, 92618
- Novartis Investigative Site
-
Lafayette, California, United States, 94549
- Novartis Investigative Site
-
San Diego, California, United States, 92126
- Novartis Investigative Site
-
Temecula, California, United States, 92591
- Novartis Investigative Site
-
-
Connecticut
-
Cromwell, Connecticut, United States, 06416
- Novartis Investigative Site
-
Hamden, Connecticut, United States, 06518
- Novartis Investigative Site
-
-
Florida
-
Bradenton, Florida, United States, 34208
- Novartis Investigative Site
-
Jacksonville, Florida, United States, 32216
- Novartis Investigative Site
-
Maitland, Florida, United States, 32751
- Novartis Investigative Site
-
Port Charlotte, Florida, United States, 33952
- Novartis Investigative Site
-
-
Georgia
-
Atlanta, Georgia, United States, 30308
- Novartis Investigative Site
-
Atlanta, Georgia, United States, 30329
- Novartis Investigative Site
-
Marietta, Georgia, United States, 30060
- Novartis Investigative Site
-
-
Kansas
-
Overland Park, Kansas, United States, 66212
- Novartis Investigative Site
-
-
Maryland
-
Rockville, Maryland, United States, 20852
- Novartis Investigative Site
-
Salisbury, Maryland, United States, 21801
- Novartis Investigative Site
-
-
Massachusetts
-
Pittsfield, Massachusetts, United States, 01201
- Novartis Investigative Site
-
-
Michigan
-
Farmington Hills, Michigan, United States, 48336
- Novartis Investigative Site
-
Rochester Hills, Michigan, United States, 48307
- Novartis Investigative Site
-
-
Missouri
-
Saint Peters, Missouri, United States, 63376
- Novartis Investigative Site
-
-
New Jersey
-
Princeton, New Jersey, United States, 08540
- Novartis Investigative Site
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87102
- Novartis Investigative Site
-
-
New York
-
Brooklyn, New York, United States, 11235
- Novartis Investigative Site
-
New York, New York, United States, 10021
- Novartis Investigative Site
-
-
Ohio
-
Beachwood, Ohio, United States, 44122
- Novartis Investigative Site
-
Dayton, Ohio, United States, 45408
- Novartis Investigative Site
-
-
Oklahoma
-
Tulsa, Oklahoma, United States, 74136
- Novartis Investigative Site
-
-
Oregon
-
Eugene, Oregon, United States, 97404
- Novartis Investigative Site
-
-
South Carolina
-
North Charleston, South Carolina, United States, 29406
- Novartis Investigative Site
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Novartis Investigative Site
-
-
Texas
-
Austin, Texas, United States, 78754
- Novartis Investigative Site
-
Dallas, Texas, United States, 75231
- Novartis Investigative Site
-
Houston, Texas, United States, 77007
- Novartis Investigative Site
-
-
Utah
-
Salt Lake City, Utah, United States, 84107
- Novartis Investigative Site
-
-
Vermont
-
Bennington, Vermont, United States, 05201
- Novartis Investigative Site
-
-
Virginia
-
Midlothian, Virginia, United States, 23112
- Novartis Investigative Site
-
-
Washington
-
Bothell, Washington, United States, 98011
- Novartis Investigative Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of Major Depressive Disorder, single or recurrent episode, according to DSM-IV criteria
- HAM-D17 total score > or = 22 at Screening and Baseline
- CGI-Severity score > or = 4 at Screening and Baseline
- Only patients who complete the core protocol are eligible to participate in the Open-Label Extension Phase
Exclusion Criteria:
- History of bipolar disorder (I or II), schizophrenia, schizoaffective disorder, eating disorder, or obsessive compulsive disorder
- Any current Axis I disorder other than major depressive disorder which is the focus of treatment
- Substance or alcohol abuse in the last 30 days, dependence in the last 6 months
- Concomitant psychotropic medication, including herbal preparations and melatonin
- Psychotherapy of any type
- Female patients of childbearing potential who are not using effective contraception
Other protocol-defined inclusion/exclusion criteria may apply
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: 1
|
|
|
Experimental: 2
|
|
|
Placebo Comparator: 3
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
To evaluate the change from Baseline to Week 8 on the total score of the clinician rated 17-Item Hamilton Depression Rating Scale (HAM-D17)
Time Frame: 8 weeks
|
8 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
To evaluate the proportion of patients who demonstrate clinical improvement at Week 8, where improvement is defined by a score of 1 or 2 on the CGI-I scale
Time Frame: 8 weeks
|
8 weeks
|
|
To evaluate the proportion of patients who achieve remission at Week 8, where remission is defined by a total score of < or =7 on the HAM-D17
Time Frame: 8 weeks
|
8 weeks
|
|
To evaluate efficacy with respect to the proportion of patients who demonstrate clinical response, where response is defined by a reduction of at least 50% in the baseline HAM-D17 at week 8
Time Frame: 8 weeks
|
8 weeks
|
|
To evaluate the change from baseline to week 8 on the subscale scores (Maier, anxiety, retardation and sleep) of the clinician-rated HAM-D17
Time Frame: 8 weeks
|
8 weeks
|
|
To evaluate subjective sleep (onset and quality), as measured by the scores on the Leeds Sleep Evaluation Questionnaire (LSEQ) at week 8
Time Frame: 8 weeks
|
8 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CAGO178A2301
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.